Since it was first recognized in 1995 [2], many de novo CD5+ DLBCL cases have been documented, and the overall incidence comprises 5–10% of all DLBCLs [1, 5, 6]. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.